A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis

Scandinavian Journal of Rheumatology

Volumn 38, Issue 2, 2009, Pages 133-143

  Dahlberg, L E ^a   Holme, I ^b   Hoye K ^c   Ringertz, B ^d  

^a LUND UNIVERSITY   (Sweden)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c Medi3 Innlandet AS   (Norway)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ACUTE KIDNEY FAILURE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; EDEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HEALTH CARE COST; HEALTH ECONOMICS; HEART ARRHYTHMIA; HEART FAILURE; HEMATEMESIS; HEMOGLOBIN BLOOD LEVEL; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; KNEE OSTEOARTHRITIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; OSTEOARTHRITIS; PAIN ASSESSMENT; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TOXIC HEPATITIS; VISUAL ANALOG SCALE;

EID: 62249194020     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740802419065     Document Type: Article

References (38)

1. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996;111:445-54.
2. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105.
3. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006;119:255-66.
4. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and metaanalysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644-65.
5. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
6. Wolfe F, Michaud K, Burke TA, Zhao SZ. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol 2004;31:355-8.
7. Zhao SZ, Wentworth C, Burke TA, Makuch RW. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf 2004;13:277-87.
8. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-18.
9. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11.
10. Goldstein JL, Eisen GM, Burke TA, Pena BM, Lefkowith J, Geis GS. Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. Aliment Pharmacol Ther 2002;16:819-27.
11. The EuroQol Group. EQ-5D. Available at: www.euroqol.org/.
12. Rabeneck L. Measuring dyspepsia-related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors. Rheumatology (Oxford) 2003;42(Suppl 3):iii32-9.
13. Rabeneck L, Wristers K, Goldstein JL, Eisen G, Dedhiya SD, Burke TA. Reliability, validity, and responsiveness of Severity of Dyspepsia Assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy. Am J Gastroenterol 2002;97:32-9.
14. LFN(SwedishPharmaceuticalBenefitsBoard).http://www.lfn.se.
15. Södra Regionvårdsnämnden, Regionala priser och ersättningar 2002 för södra sjukvårdsregionen (MAS). Available at: www.srvn.org.
16. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
17. PhRMA Clinical Study Synopsis, CLASS study. 2006. Available at: www.clinicalstudyresults.org/documents/company-study-1841-0.pdf.
18. Maddrey WC, Maurath CJ, Verburg KM, Geis GS. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 2000;7:153-8.
19. Penninx BW, Pahor M, Woodman RC, Guralnik JM. Anemia in old age is associated with increased mortality and hospitalization. J Gerontol A Biol Sci Med Sci 2006;61:474-9.
20. Penninx BW, Guralnik JM, Onder G, Ferrucci L, Wallace RB, Pahor M. Anemia and decline in physical performance among older persons. Am J Med 2003;115:104-10.
21. Penninx BW, Pahor M, Cesari M, Corsi AM, Woodman RC, Bandinelli S, et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc 2004;52:719-24.
22. Chaves PH, Semba RD, Leng SX, Woodman RC, Ferrucci L, Guralnik JM, et al. Impact of anemia and cardiovascular disease on frailty status of community-dwelling older women: the Women's Health and Aging Studies I and II. J Gerontol A Biol Sci Med Sci 2005;60:729-35.
23. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000;7:159-75.
24. Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int 2006;70:1495-502.
25. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
26. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
27. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
28. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
29. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
30. Martin BK, Breitner JCS, Evans D, Lyketsos CG, Meinert CL; ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled, Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1:e33.
31. White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007;99:91-8.
32. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89:425-30.
33. El Serag HB, Graham DY, Richardson P, Inadomi JM. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med 2002;162:2105-10.
34. Zabinski RA, Burke TA, Johnson J, Lavoie F, Fitzsimon C, Tretiak R, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001;19(Suppl 1):49-58.
35. Health Canada. Arthritis in Canada: an ongoing challenge. Ottawa: Health Canada, 2003. Cat. no H39-4/14-2003E. http://www.phac-aspc.gc.ca/publicat/ac/ pdf/ac-e.pdf.
36. Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ, Goldstein JL. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics 2001;19(Suppl 1):33-47.
37. Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003;49:283-92.
38. Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The costeffectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003;138:795-806.